Literature DB >> 27307436

Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR.

Daniel J Munson1, Colt A Egelston2, Kami E Chiotti3, Zuly E Parra1, Tullia C Bruno1, Brandon L Moore1, Taizo A Nakano1, Diana L Simons2, Grecia Jimenez2, John H Yim4, Dmitri V Rozanov3, Michael T Falta5, Andrew P Fontenot6, Paul R Reynolds7, Sonia M Leach8, Virginia F Borges9, John W Kappler10, Paul T Spellman3, Peter P Lee2, Jill E Slansky11.   

Abstract

Infiltration of T cells in breast tumors correlates with improved survival of patients with breast cancer, despite relatively few mutations in these tumors. To determine if T-cell specificity can be harnessed to augment immunotherapies of breast cancer, we sought to identify the alpha-beta paired T-cell receptors (TCRs) of tumor-infiltrating lymphocytes shared between multiple patients. Because TCRs function as heterodimeric proteins, we used an emulsion-based RT-PCR assay to link and amplify TCR pairs. Using this assay on engineered T-cell hybridomas, we observed ∼85% accurate pairing fidelity, although TCR recovery frequency varied. When we applied this technique to patient samples, we found that for any given TCR pair, the dominant alpha- or beta-binding partner comprised ∼90% of the total binding partners. Analysis of TCR sequences from primary tumors showed about fourfold more overlap in tumor-involved relative to tumor-free sentinel lymph nodes. Additionally, comparison of sequences from both tumors of a patient with bilateral breast cancer showed 10% overlap. Finally, we identified a panel of unique TCRs shared between patients' tumors and peripheral blood that were not found in the peripheral blood of controls. These TCRs encoded a range of V, J, and complementarity determining region 3 (CDR3) sequences on the alpha-chain, and displayed restricted V-beta use. The nucleotides encoding these shared TCR CDR3s varied, suggesting immune selection of this response. Harnessing these T cells may provide practical strategies to improve the shared antigen-specific response to breast cancer.

Entities:  

Keywords:  T-cell receptors; T-cell repertoire profiling; breast cancer; emulsion RT-PCR; high-throughput sequencing

Mesh:

Substances:

Year:  2016        PMID: 27307436      PMCID: PMC4961128          DOI: 10.1073/pnas.1606994113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status.

Authors:  J L Mccoy; R Rucker; J A Petros
Journal:  Breast Cancer Res Treat       Date:  2000-04       Impact factor: 4.872

Review 2.  Tumor microenvironment is multifaceted.

Authors:  Catherine Sautès-Fridman; Julien Cherfils-Vicini; Diane Damotte; Sylvain Fisson; Wolf Hervé Fridman; Isabelle Cremer; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

3.  TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture.

Authors:  P Y Dietrich; P R Walker; V Schnuriger; P Saas; G Perrin; M Guillard; C Gaudin; A Caignard
Journal:  Int Immunol       Date:  1997-08       Impact factor: 4.823

4.  Overlap and effective size of the human CD8+ T cell receptor repertoire.

Authors:  Harlan S Robins; Santosh K Srivastava; Paulo V Campregher; Cameron J Turtle; Jessica Andriesen; Stanley R Riddell; Christopher S Carlson; Edus H Warren
Journal:  Sci Transl Med       Date:  2010-09-01       Impact factor: 17.956

Review 5.  Recombination centres and the orchestration of V(D)J recombination.

Authors:  David G Schatz; Yanhong Ji
Journal:  Nat Rev Immunol       Date:  2011-03-11       Impact factor: 53.106

6.  Amplification of complex gene libraries by emulsion PCR.

Authors:  Richard Williams; Sergio G Peisajovich; Oliver J Miller; Shlomo Magdassi; Dan S Tawfik; Andrew D Griffiths
Journal:  Nat Methods       Date:  2006-07       Impact factor: 28.547

7.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences.

Authors:  Jeremy Goecks; Anton Nekrutenko; James Taylor
Journal:  Genome Biol       Date:  2010-08-25       Impact factor: 13.583

8.  HLA class I supertypes: a revised and updated classification.

Authors:  John Sidney; Bjoern Peters; Nicole Frahm; Christian Brander; Alessandro Sette
Journal:  BMC Immunol       Date:  2008-01-22       Impact factor: 3.615

9.  Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing.

Authors:  Miran Jang; Poh-Yin Yew; Kosei Hasegawa; Yuji Ikeda; Keiichi Fujiwara; Gini F Fleming; Yusuke Nakamura; Jae-Hyun Park
Journal:  Oncoimmunology       Date:  2015-04-14       Impact factor: 8.110

10.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Authors:  H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas
Journal:  Ann Oncol       Date:  2014-06-09       Impact factor: 32.976

View more
  33 in total

Review 1.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Comparative analysis of murine T-cell receptor repertoires.

Authors:  Mark Izraelson; Tatiana O Nakonechnaya; Bruno Moltedo; Evgeniy S Egorov; Sofya A Kasatskaya; Ekaterina V Putintseva; Ilgar Z Mamedov; Dmitriy B Staroverov; Irina I Shemiakina; Maria Y Zakharova; Alexey N Davydov; Dmitriy A Bolotin; Mikhail Shugay; Dmitriy M Chudakov; Alexander Y Rudensky; Olga V Britanova
Journal:  Immunology       Date:  2017-11-27       Impact factor: 7.397

3.  Biophysicochemical Motifs in T-cell Receptor Sequences Distinguish Repertoires from Tumor-Infiltrating Lymphocyte and Adjacent Healthy Tissue.

Authors:  Jared Ostmeyer; Scott Christley; Inimary T Toby; Lindsay G Cowell
Journal:  Cancer Res       Date:  2019-01-08       Impact factor: 12.701

4.  Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients.

Authors:  Colt A Egelston; Christian Avalos; Travis Y Tu; Anthony Rosario; Roger Wang; Shawn Solomon; Gayathri Srinivasan; Michael S Nelson; Yinghui Huang; Min Hui Lim; Diana L Simons; Ting-Fang He; John H Yim; Laura Kruper; Joanne Mortimer; Susan Yost; Weihua Guo; Christopher Ruel; Paul H Frankel; Yuan Yuan; Peter P Lee
Journal:  JCI Insight       Date:  2019-10-03

Review 5.  T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.

Authors:  David Schrama; Cathrin Ritter; Jürgen C Becker
Journal:  Semin Immunopathol       Date:  2017-01-10       Impact factor: 9.623

6.  Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges.

Authors:  Kavita Dhodapkar; Madhav Dhodapkar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-07       Impact factor: 11.205

7.  Shared αβ TCR Usage in Lungs of Sarcoidosis Patients with Löfgren's Syndrome.

Authors:  Angela M Mitchell; Ylva Kaiser; Michael T Falta; Daniel J Munson; Laurie G Landry; Anders Eklund; Maki Nakayama; Jill E Slansky; Johan Grunewald; Andrew P Fontenot
Journal:  J Immunol       Date:  2017-08-21       Impact factor: 5.422

Review 8.  T-cell receptor affinity in the age of cancer immunotherapy.

Authors:  Michele M Hoffmann; Jill E Slansky
Journal:  Mol Carcinog       Date:  2020-05-09       Impact factor: 4.784

Review 9.  Ushering in Integrated T Cell Repertoire Profiling in Cancer.

Authors:  Ning Jiang; Alexandra A Schonnesen; Ke-Yue Ma
Journal:  Trends Cancer       Date:  2018-12-26

10.  Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.

Authors:  Takemasa Tsuji; Akira Yoneda; Junko Matsuzaki; Anthony Miliotto; Courtney Ryan; Richard C Koya; Kunle Odunsi
Journal:  Cancer Immunol Res       Date:  2018-03-27       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.